

Basilea Pharmaceutica

BARDA backs latest antibacterial programme

Funding update

Healthcare

29 September 2025

Basilea Pharmaceutica has secured a BARDA contract of up to **\$159m** to advance ceftibuten-ledaborbactam etzadroxil, its recently in-licensed oral, Phase III-ready antibiotic for complicated urinary tract infections (cUTIs). The agreement replaces the original BARDA deal with the licensee Venatorx (**October 2023**) and provides \$6m in committed near-term funding, with a further up to \$153m in milestone-based payments, including support for the planned Phase III programme. We believe that this development meaningfully reduces clinical and funding risk for ceftibuten-ledaborbactam, which holds fast track and qualified infectious disease product designations from the FDA. Basilea has also recently received a commitment for a third **\$25m** tranche under its separate \$268m OTA funding agreement with BARDA (\$93m committed to date), further validating its anti-infective pipeline.

Year end	Revenue (CHFm)	EBITDA (CHFm)	PBT (CHFm)	EPS (CHF)	DPS (CHF)	EV/EBITDA (x)	P/E (x)
12/23	157.6	20.8	10.8	0.90	0.00	26.5	50.4
12/24	208.5	62.9	60.6	6.44	0.00	8.8	7.0
12/25e	225.1	51.7	46.5	3.41	0.00	10.7	13.3
12/26e	254.3	71.0	69.7	5.14	0.00	7.8	8.8

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.


Basilea has a longstanding relationship with BARDA on two of its lead programmes, with Zevtera and fosmanogepix having already received R&D backing for their respective Phase III programmes. We believe that, when fully realised, the latest non-dilutive funding will cover a significant portion of Phase III development costs for the asset, significantly de-risking clinical progression.

While Basilea is yet to disclose its Phase III design for ceftibuten-ledaborbactam, we estimate that a single Phase III trial would need to recruit 1,000–1,500 patients and more than one trial may be required. Ceftibuten-ledaborbactam is a beta-lactam/ beta lactamase inhibitor (BL/BLI) combination and its oral administration and activity against multidrug-resistant Enterobacterales (ESBL, KPC, OXA-48) positions it for use in both outpatient and step-down hospital settings, a cUTI market estimated at **c \$3bn by 2035**. While there are BL/BLI combinations available for cUTI, no oral formulations targeting multidrug-resistant pathogens have been approved to date, creating a material commercial opportunity for ceftibuten-ledaborbactam, if approved. We estimate global peak sales potential of US\$400–500m for the treatment.

This development follows the recent \$25m funding commitment from BARDA under its Other Transaction Agreement (OTA) signed in September 2024. It marked the third successive payment under the OTA to Basilea following the \$29m received at signing and another \$39m in July. In total, Basilea has received commitments for \$93m of the up to \$268m earmarked under the agreement. This latest tranche was triggered by fosmanogepix reaching a predetermined enrolment milestone in its Phase III trial (in invasive yeast infections). The proceeds will support the ongoing Phase III fosmanogepix programme and the planned Phase II trial for BAL2062. BARDA is expected to fund 60% of the development costs for programmes covered under the OTA, including fosmanogepix and BAL2062.

Price	CHF45.20
Market cap	CHF602m
	US\$1.25/CHF
Net cash at 30 June 2025	CHF50.7m
Shares in issue	13.3m
Code	BSLN
Primary exchange	SWX
Secondary exchange	N/A

Share price performance



Business description

Basilea Pharmaceutica is focused on treating infectious diseases. Its marketed products are Cresemba (an antifungal) and Zevtera (an anti-MRSA broad-spectrum antibiotic). It also has a broad development pipeline that includes two antifungals: Phase III novel broad-spectrum treatment fosmanogepix (two Phase III trials ongoing) and Phase II asset BAL2062; and two antibacterials: preclinical LptA inhibitor BAL2420 and recently acquired Phase III-ready oral combination treatment ceftibuten-ledaborbactam etzadroxil.

Analysts

Jyoti Prakash, CFA	+44 (0)20 3077 5700
Arron Aatkar, PhD	+44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

**Basilea Pharmaceutica is
a research client of Edison
Investment Research Limited**

General disclaimer and copyright

This report has been commissioned by Basilea Pharmaceutica and prepared and issued by Edison, in consideration of a fee payable by Basilea Pharmaceutica. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2025 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
